Biological characteristics and transcriptomic profile of adipose-derived mesenchymal stem cells isolated from

Mohammed Zayed1,2,3, Yong-Chan Kim4,5, Byung-Hoon Jeong6,7

  • 1Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, 54531, Republic of Korea.

PubMed
Abstract

Insights

Adipose-derived mesenchymal stem cells (AdMSCs) from prion-infected mice showed reduced viability and impaired function. Further research is needed to explore therapeutic strategies using AdMSCs for prion diseases.

Area of Science:

  • Neuroscience
  • Stem Cell Biology
  • Infectious Diseases

Background:

  • Prion diseases involve misfolded prion protein aggregates in the brain.
  • Mesenchymal stem cells (MSCs) are explored for prion disease therapy.
  • Adipose-derived MSCs (AdMSCs) response to prion infection requires study due to prion presence in fat tissue.

Purpose of the Study:

  • To analyze the properties of AdMSCs from prion-infected mice.
  • To compare AdMSCs from infected and control mice.
  • To assess the impact of prion infection on AdMSC characteristics and gene expression.

Main Methods:

  • AdMSCs were isolated from ME7 scrapie strain-infected mice and controls.
  • Evaluated morphology, viability, immunophenotype, inflammation markers, migration, and neurotrophic factors.
  • RNA sequencing (RNA-Seq) was used for transcriptome profiling.

Main Results:

  • Infected AdMSCs were larger with lower viability and altered immunophenotype (reduced CXCR4).
  • Increased expression of inflammatory mediators (CCL5, TNF-α, C3, IL6) and decreased migration activity were observed.
  • RNA-Seq revealed differentially expressed genes, enriched pathways (PI3K-Akt, cell adhesion), and upregulated iron storage genes (Hp, hepcidin).

Conclusions:

  • Prion infection significantly alters AdMSC properties, including viability, migration, and gene expression.
  • These findings suggest potential risks and limitations for AdMSC-based prion disease therapies.
  • Further investigation into therapeutic strategies involving AdMSCs for prion diseases is warranted.